Stockscreener 앱 받기
0.75
0.00%
0.00
전일 마감가:
$0.75
열려 있는:
$0.766
하루 거래량:
47,707
Relative Volume:
0.30
시가총액:
$3.77M
수익:
$72,100
순이익/손실:
$-3.60M
주가수익비율:
-0.6303
EPS:
-1.19
순현금흐름:
$-3.37M
1주 성능:
-10.72%
1개월 성능:
-30.56%
6개월 성능:
-32.43%
1년 성능:
-59.46%
1일 변동 폭
$0.74
$0.77
1주일 범위
$0.71
$0.8799
52주 변동 폭
$0.71
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
명칭
Silo Pharma Inc
전화
(718) 400-9031
주소
677 N. WASHINGTON BLVD, SARASOTA
SILO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.28 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1555 | 349.69M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.2267 | 318.40M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
10.85 | 205.55M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.00 | 157.18M | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc 주식(SILO)의 최신 뉴스
Contrasting Silo Pharma (SILO) and Its Competitors - Defense World
Silo Pharma's SP-26 Implant Achieves All Endpoints In Preclinical Fibromyalgia Study - Nasdaq
EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models - AOL.com
Silo Pharma stock hits 52-week low at $0.76 amid market challenges - Investing.com Australia
SILO Pharma Achieves Milestone with Promising Preclinical Results for SP-26 | SILO Stock News - GuruFocus
Silo Pharma reports positive preclinical results for SP-26 - Investing.com
Silo Pharma Announces Positive Preclinical Results for SP-26, a Novel Extended-Release Ketamine Implant for Fibromyalgia - Nasdaq
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study - marketscreener.com
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study - GlobeNewswire
Revolutionary Ketamine Implant Could Replace Opioids for Fibromyalgia Treatment, Study Shows - Stock Titan
A Guide To The Risks Of Investing In SILO Pharma Inc (SILO) - knoxdaily.com
The Significance of Moving Averages in SILO Pharma Inc Inc. (SILO) Price Performance - investchronicle.com
SILO Pharma Inc (SILO) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Balance Sheet Insights: SILO Pharma Inc (SILO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Silo Pharma files patent for Alzheimer’s treatment - Investing.com Australia
Silo Pharma files patent for Alzheimer’s treatment By Investing.com - Investing.com India
Sarasota company applies for Alzheimer's drug patent - Business Observer
Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer'S Drug - marketscreener.com
Silo Pharma (SILO) Files Patent for Innovative Alzheimer's Treatment | SILO Stock News - GuruFocus
Silo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of Action - Nasdaq
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug - GlobeNewswire
Groundbreaking Alzheimer's Treatment Patent: Columbia-Licensed Drug Targets Multiple Brain Pathways - Stock Titan
Silo Pharma (SILO) versus The Competition Financial Analysis - Defense World
Silo Pharma (SILO) versus Its Rivals Financial Analysis - Defense World
Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease - Psychedelic Alpha
Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Increases By 38.7% - Defense World
Silo Pharma Inc. (SILO) reports earnings - Quartz
Silo Pharma, Inc. SEC 10-K Report - TradingView
SILO Stock Price and Chart — NASDAQ:SILO - TradingView
Silo Pharma begins key study for PTSD treatment By Investing.com - Investing.com South Africa
Silo Pharma Doses First Participant In IND-Enabling GLP Study Of SPC-15 For PTSD Treatment - Nasdaq
Silo Pharma begins key study for PTSD treatment - Investing.com
Silo Pharma Achieves Key Milestone With First Dosing In IND-Enabling GLP Study For SPC-15 As A Groundbreaking PTSD Treatment - Marketscreener.com
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - The Manila Times
Major PTSD Treatment Advance: FDA Fast-Track Path Opens for Revolutionary Drug SPC-15 - Stock Titan
Silo Pharma Unveils Strategic Initiatives and Drug Pipeline - TipRanks
Silo Pharma secures patent for stress disorder prophylactic - Investing.com
Silo Pharma secures patent for stress disorder prophylactic By Investing.com - Investing.com UK
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment - Marketscreener.com
MarketsMedicine Hat News - Financial Content
Silo Pharma Granted US Patent for Intranasal Post-Traumatic Stress Disorder Treatment - Marketscreener.com
Silo Pharma, Inc. Receives Issuance Notification for Patent Related to SPC-15 Treatment for PTSD - Nasdaq
Silo Files Provisional Patent For SPC-15 Combination Treatment To Target Stress-Induced Disorders - Nasdaq
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - The Manila Times
Silo Pharma Expands Intellectual Property Portfolio with - GlobeNewswire
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for ... - The Bakersfield Californian
Revolutionary Mental Health Treatment Patent: Silo Pharma's Dual-Action SPC-15 Shows Promising Results - StockTitan
Silo Pharma reports positive early data on pain treatment implant By Investing.com - Investing.com Nigeria
Silo Pharma Announces Positive Initial Pharmacokinetic, - GlobeNewswire
Silo Pharma reports positive early data on pain treatment implant - Investing.com
SILO’s valuation metrics: A comprehensive analysis - US Post News
Silo Pharma Inc (SILO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Silo Pharma Inc 주식 (SILO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | CEO and President |
Nov 20 '24 |
Buy |
0.95 |
2,500 |
2,375 |
182,932 |
| Weisblum Eric | CEO and President |
Nov 22 '24 |
Buy |
0.90 |
2,500 |
2,250 |
185,432 |
| Weisblum Eric | CEO and President |
Jun 12 '24 |
Buy |
1.11 |
4,438 |
4,926 |
180,432 |
| Weisblum Eric | CEO and President |
Jun 11 '24 |
Buy |
1.08 |
562 |
607 |
175,994 |
0.37%
0.04%
자본화:
|
볼륨(24시간):